BJCT-BIOJECT-needle less injection product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: geewiz who wrote (263)	7/22/1998 10:56:00 AM
From: Marc Kahn	Read Replies (1) of 534

Hi Art, To answer your questions: <I'm glad to hear that we are getting 1.5 million from MRK, I missed that in the press release.> That's because it wasn't in the press release. It came out in the conference call which followed the press release. It is a $1.5M up-front payment which gives Merck the right to negotiate with Bioject about specific vaccines. < Has this commitment been made for particular vaccines?> Not yet, but I understand that negotiations are under way. < The ISO certification must be a done deal for MRK to make such a commitment, was there a press release on this?> I haven't heard anything about this either. However, I visited the company in February, for the special shareholders meeting. During a tour of the facility after the meeting, the fellow who was leading the tour said that all the paperwork was in place for ISO certification. <Anyone have impressions of the new CFO?> I haven't yet met or talked to Mike Temple, but I have heard positive comments from people who have. Regards, Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next